Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
Deutsche Version Deutsche Version
  MedUni Vienna    Intranet    MedUni Vienna - Shop    University Library    University Hospital Vienna  
 
Krebsforschung_EN.png
 
 
 
Hauptnavigation
  • Home
  • General Information
    • History
    • 50 years Institute for Cancer Research
    • Imagevideo: Institute for Cancer Research
  • Research
    • Research Focus
    • Research Laboratories
    • Scientific Services - Core Facilities
  • Teaching
    • Lectures of the Institute of Cancer Research
    • University Course Toxicology for Postgraduates
    • PhD Program Inflammation and Immunity
    • PhD Program IPPTO Translational Oncology
    • PhD Program Malignant Diseases
    • PhD Program Clinical and Experimental Oncology
  • Contact
    • Contact
    • Map
 
Research / Research Focus / Applied and Experimental Oncology / Michael Grusch
 
Subnavigation
  • Research Focus
    • Cellular and Molecular Tumorbiology
    • Applied and Experimental Oncology
      • Walter Berger
      • Martin Filipits
      • Petra Heffeter
      • Michael Grusch
        • Research Projects
        • Group Members
        • Teaching
      • Klaus Holzmann
      • Hedwig Sutterlüty
    • Chemical Safety and Cancer Prevention
    • Tumor Progression and Metastasis
  • Research Laboratories
  • Scientific Services - Core Facilities


Inhaltsbereich

 

Michael Grusch, Assoc. Prof. Priv.-Doz. Mag. Dr.
Group Leader

E-Mail: michael.grusch [at] meduniwien [dot] ac [dot] at
Phone: +43 (0)1 40160 - 57556
Fax: +43 (0)1 40160 - 957555

Research Focus

Our research is focused on growth factors and their receptors involved in cancer cell growth and drug resistance. We aim to (1.) understand how growth factor signals contribute to malignancy (2.) translate this knowledge into strategies for therapeutic interventions and (3.) characterize the mechanisms that determine sensitivity or resistance of tumors to molecularly targeted therapeutics.
Within this area we are interested on the one hand in receptor tyrosine kinases (RTKs) of the fibroblast growth factor receptor (FGFR) and epidermal growth factor recetor (EGFR, erbb) families which are (over)activated in many human cancer types and on the other hand in activins. The latter are cytokines of the transforming growth factor (TGF) beta family and act as regulators of cell differentiation and cell death in a tissue-specific manner. Their activity is stringently controlled by antagonistic follistatin proteins.



Group Members

Videos

Selected Publications:

FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal. Schelch K, Wagner C, Hager S, Pirker C, Siess K, Lang E, Lin R, Kirschner MB, Mohr T, Brcic L, Marian B, Holzmann K, Grasl-Kraupp B, Krupitza G, Laszlo V, Klikovits T, Dome B, Hegedus B, Garay T, Reid G, van Zandwijk N, Klepetko W, Berger W, Grusch M, Hoda MA.
Carcinogenesis. 2018 Apr 5;39(4):534-545

FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo. Ghassemi S, Vejdovszky K, Sahin E, Ratzinger L, Schelch K, Mohr T, Peter-Vörösmarty B, Brankovic J, Lackner A, Leopoldi A, Meindl D, Pirker C, Hegedus B, Marian B, Holzmann K, Grasl-Kraupp B, Heffeter P, Berger W, Grusch M.
Oncotarget. 2017 Sep 23;8(50):87750-87762

Light-assisted small-molecule screening against protein kinases.
Inglés-Prieto Á, Reichhart E, Muellner MK, Nowak M, Nijman SM, Grusch M, Janovjak H.;
Nat Chem Biol. 2015 Oct 12

The Optogenetic Promise for Oncology: Episode I
Ingles-Prieto A, Reichhart E, Schelch K, Janovjak H, Grusch M.;
Molecular and Cellular Oncology (2014), DOI:10.4161/23723548.2014.964045

Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy.
Schelch K, Hoda MA, Klikovits T, Münzker J, Ghanim B, Wagner C, Garay T, Laszlo V, Setinek U, Dome B, Filipits M, Pirker C, Heffeter P, Selzer E, Tovari J, Torok S, Kenessey I, Holzmann K, Grasl-Kraupp B, Marian B, Klepetko W, Berger W, Hegedus B, Grusch M.;
Am J Respir Crit Care Med. 2014 Oct 1;190(7):763-72

Spatio-temporally precise activation of engineered receptor tyrosine kinases by light.
Grusch M, Schelch K, Riedler R, Reichhart E, Differ C, Berger W, Inglés-Prieto Á, Janovjak H.;
EMBO J. 2014 Aug 1;33(15):1713-26

Bay11-7082 inhibits the disintegration of the lymphendothelial barrier triggered by MCF-7 breast cancer spheroids; the role of ICAM-1 and adhesion.
Viola K, Kopf S, Huttary N, Vonach C, Kretschy N, Teichmann M, Giessrigl B, Raab I, Stary S, Krieger S, Keller T, Bauer S, Hantusch B, Szekeres T, de Martin R, Jäger W, Mikulits W, Dolznig H, Krupitza G, Grusch M.;
Br J Cancer. 2013 Feb 19;108(3):564-9

 

 

All Publications

PubmedDatabase

 
Print
 
 
© MedUni Wien | Publishing information | Terms of use | Data Protection | Accessibility | Contact